Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Validating non-linguistic laboratory biomarkers of depression in persons with aphasia

Award Number: R03HD111008
ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2024
PERIOD OF PERFORMANCE END DATE: 02/28/2027

Group Awards By:

View Award Description

Validating non-linguistic laboratory biomarkers of depression in persons with aphasia - Aphasia is a multi-modality disturbance of language that is more common than disorders such as Parkinson’s disease and has a greater negative impact on quality of life than Alzheimer’s disease and many cancers. Persons with Aphasia (PWAs) are thought to be at a higher risk for depression than other stroke survivors. Depression is also thought to worsen language and cognitive performance in PWAs and decrease their quality of life. However, identifying depression in PWAs is challenging as their language disturbances make it difficult to assess depressive symptoms using traditional methods such as questionnaires and interviews as these methods require PWAs to report on their inner experiences (e.g., their sadness, experience of pleasure, etc.). An alternative approach to diagnostic interviews or questionnaires is to utilize laboratory-assessed biomarkers that require minimal language abilities and have shown to robustly identify depression in neurologically healthy individuals. A goal of this study is thus to assess the ability of three laboratory tests to detect depression in PWAs (N=46): (a) heart-rate variability at rest, (b) pupil dilation, and (c) gaze duration (a measure of biased attention) to negatively and positively valenced images. A challenge of this study is that without a gold-standard way to assess depression in PWAs, it is difficult to truly know whether the three biomarkers are validly assessing depression in people who have difficulty verbally reporting on their inner experiences. Aim 1 of the study will therefore apply a novel convergent validity approach and use as its validator a composite reference standard based on multiple indicators or proxies of depression - specifically, informant (e.g., family member, caregiver) report of PWAs (a) depression symptoms, (b) pre-morbid history of PWAs depression (a robust predictor of future depression in non-neurological and neurological patients), and (c) a self-report depression scale adapted for PWAs. Composite reference standards are routinely employed to evaluate new tests when gold-standard and imperfect diagnostic tests exist, but this approach has not been used to assess depression in PWA. Aim 2 will test whether laboratory- assessed biomarkers predict PWAs day-to-day experiences of affect and social interaction (a critical factor for successful rehabilitation), using experience sampling methodology (ESM). ESM is an approach that requires brief, frequent (multiple per day), at-home assessments (in this case, from caregivers). ESM minimizes recall bias and increases ecological validity of assessments. Lastly, aim 3 will establish the retest reliability of laboratory-assessed biomarkers of depression by re-administering all measures to PWAs 7 days later. The proposed project has the potential for high impact for PWAs since accurate diagnosis of depression in PWAs can lead to better management of depression, which can positively impact linguistic and cognitive functioning and improve PWA’s quality of life. The project will lay the foundation for a future research platform for the early- stage PI that examines whether the laboratory-assessed biomarkers predict different depression treatment responses and language and functional improvements related to the treatments longitudnally.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2024	REHABILITATION INSTITUTE OF CHICAGO	355 E ERIE ST	CHICAGO	IL	60611	COOK	USA	Child Health and Human Development Extramural Research	000	1	8/7/2026	NEW	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $344,357 )
2024	2024	REHABILITATION INSTITUTE OF CHICAGO	355 E ERIE ST	CHICAGO	IL	60611	COOK	USA	Child Health and Human Development Extramural Research	001	1	9/10/2024	NEW	$0
2024	2024	REHABILITATION INSTITUTE OF CHICAGO	355 E ERIE ST	CHICAGO	IL	60611	COOK	USA	Child Health and Human Development Extramural Research	000	1	8/8/2024	NEW	$344,357
														Subtotal = $344,357

Grand Total All Awards = $344,357

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Validating non-linguistic laboratory biomarkers of depression in persons with aphasia

Award Number: R03HD111008

ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2024

PERIOD OF PERFORMANCE END DATE: 02/28/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer